A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer

Masahiro Tabata, Katsuyuki Kiura, Niro Okimoto, Yoshihiko Segawa, Tetsu Shinkai, Toshiro Yonei, Shoichi Kuyama, Shingo Harita, Katsuyuki Hotta, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The aim of this trial was to investigate the efficacy and safety of cisplatin (P) and irinotecan (I) (PI) alternating with doxorubicin (A), cyclophosphamide (C) and etoposide (E) (ACE) in patients with extensive-disease small-cell lung cancer (ED-SCLC). Patients and Methods: Patients with previously untreated ED-SCLC were enrolled in this trial. In the first, third and fifth cycles, PI (P: 60 mg/m2 on day 1; I: 60 mg/m2/day on days 1, 8 and 15) was administered, whereas ACE (A: 50 mg/m2 on day 1; C: 750 mg/m2 on day 1; E 80 mg/m2/day on days 1-3) was given in the second, fourth and sixth cycles. Each cycle was repeated every 4 weeks. At the end of six cycles, patients who had obtained a complete response were given prophylactic cranial irradiation. Results: In total, 28 patients were enrolled, of whom 27 were assessable for efficacy and safety. Objective responses, including 4 (15%) complete responses, were observed in 25 patients (93%). Median survival time was 12.9 months. The principal toxicity was myelosuppression; grade 4 neutropenia and thrombocytopenia were observed in 89 and 4%, respectively. Febrile neutropenia occurred in 30% of patients. Diarrhea was mild (grade 3-4; 4%). All toxicities were reversible and there were no treatment-related deaths. The mean percentage of the delivered doses, relative to the projected doses, of PI and ACE were 84.6 and 91.1%, respectively. Conclusions: These results indicate the PI-ACE regimen to have promising activity against ED-SCLC with moderate toxicities.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume60
Issue number1
DOIs
Publication statusPublished - Jun 2007

Fingerprint

irinotecan
Small Cell Lung Carcinoma
Etoposide
Doxorubicin
Cyclophosphamide
Cisplatin
Toxicity
Cells
Irradiation
Cranial Irradiation
Safety
Febrile Neutropenia
Neutropenia

Keywords

  • Alternating chemotherapy
  • Irinotecan
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. / Tabata, Masahiro; Kiura, Katsuyuki; Okimoto, Niro; Segawa, Yoshihiko; Shinkai, Tetsu; Yonei, Toshiro; Kuyama, Shoichi; Harita, Shingo; Hotta, Katsuyuki; Ueoka, Hiroshi; Tanimoto, Mitsune.

In: Cancer Chemotherapy and Pharmacology, Vol. 60, No. 1, 06.2007, p. 1-6.

Research output: Contribution to journalArticle

Tabata, Masahiro ; Kiura, Katsuyuki ; Okimoto, Niro ; Segawa, Yoshihiko ; Shinkai, Tetsu ; Yonei, Toshiro ; Kuyama, Shoichi ; Harita, Shingo ; Hotta, Katsuyuki ; Ueoka, Hiroshi ; Tanimoto, Mitsune. / A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. In: Cancer Chemotherapy and Pharmacology. 2007 ; Vol. 60, No. 1. pp. 1-6.
@article{e258c317a0384f548d7bde6eafc1ffea,
title = "A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer",
abstract = "Purpose: The aim of this trial was to investigate the efficacy and safety of cisplatin (P) and irinotecan (I) (PI) alternating with doxorubicin (A), cyclophosphamide (C) and etoposide (E) (ACE) in patients with extensive-disease small-cell lung cancer (ED-SCLC). Patients and Methods: Patients with previously untreated ED-SCLC were enrolled in this trial. In the first, third and fifth cycles, PI (P: 60 mg/m2 on day 1; I: 60 mg/m2/day on days 1, 8 and 15) was administered, whereas ACE (A: 50 mg/m2 on day 1; C: 750 mg/m2 on day 1; E 80 mg/m2/day on days 1-3) was given in the second, fourth and sixth cycles. Each cycle was repeated every 4 weeks. At the end of six cycles, patients who had obtained a complete response were given prophylactic cranial irradiation. Results: In total, 28 patients were enrolled, of whom 27 were assessable for efficacy and safety. Objective responses, including 4 (15{\%}) complete responses, were observed in 25 patients (93{\%}). Median survival time was 12.9 months. The principal toxicity was myelosuppression; grade 4 neutropenia and thrombocytopenia were observed in 89 and 4{\%}, respectively. Febrile neutropenia occurred in 30{\%} of patients. Diarrhea was mild (grade 3-4; 4{\%}). All toxicities were reversible and there were no treatment-related deaths. The mean percentage of the delivered doses, relative to the projected doses, of PI and ACE were 84.6 and 91.1{\%}, respectively. Conclusions: These results indicate the PI-ACE regimen to have promising activity against ED-SCLC with moderate toxicities.",
keywords = "Alternating chemotherapy, Irinotecan, Small-cell lung cancer",
author = "Masahiro Tabata and Katsuyuki Kiura and Niro Okimoto and Yoshihiko Segawa and Tetsu Shinkai and Toshiro Yonei and Shoichi Kuyama and Shingo Harita and Katsuyuki Hotta and Hiroshi Ueoka and Mitsune Tanimoto",
year = "2007",
month = "6",
doi = "10.1007/s00280-006-0336-0",
language = "English",
volume = "60",
pages = "1--6",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer

AU - Tabata, Masahiro

AU - Kiura, Katsuyuki

AU - Okimoto, Niro

AU - Segawa, Yoshihiko

AU - Shinkai, Tetsu

AU - Yonei, Toshiro

AU - Kuyama, Shoichi

AU - Harita, Shingo

AU - Hotta, Katsuyuki

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

PY - 2007/6

Y1 - 2007/6

N2 - Purpose: The aim of this trial was to investigate the efficacy and safety of cisplatin (P) and irinotecan (I) (PI) alternating with doxorubicin (A), cyclophosphamide (C) and etoposide (E) (ACE) in patients with extensive-disease small-cell lung cancer (ED-SCLC). Patients and Methods: Patients with previously untreated ED-SCLC were enrolled in this trial. In the first, third and fifth cycles, PI (P: 60 mg/m2 on day 1; I: 60 mg/m2/day on days 1, 8 and 15) was administered, whereas ACE (A: 50 mg/m2 on day 1; C: 750 mg/m2 on day 1; E 80 mg/m2/day on days 1-3) was given in the second, fourth and sixth cycles. Each cycle was repeated every 4 weeks. At the end of six cycles, patients who had obtained a complete response were given prophylactic cranial irradiation. Results: In total, 28 patients were enrolled, of whom 27 were assessable for efficacy and safety. Objective responses, including 4 (15%) complete responses, were observed in 25 patients (93%). Median survival time was 12.9 months. The principal toxicity was myelosuppression; grade 4 neutropenia and thrombocytopenia were observed in 89 and 4%, respectively. Febrile neutropenia occurred in 30% of patients. Diarrhea was mild (grade 3-4; 4%). All toxicities were reversible and there were no treatment-related deaths. The mean percentage of the delivered doses, relative to the projected doses, of PI and ACE were 84.6 and 91.1%, respectively. Conclusions: These results indicate the PI-ACE regimen to have promising activity against ED-SCLC with moderate toxicities.

AB - Purpose: The aim of this trial was to investigate the efficacy and safety of cisplatin (P) and irinotecan (I) (PI) alternating with doxorubicin (A), cyclophosphamide (C) and etoposide (E) (ACE) in patients with extensive-disease small-cell lung cancer (ED-SCLC). Patients and Methods: Patients with previously untreated ED-SCLC were enrolled in this trial. In the first, third and fifth cycles, PI (P: 60 mg/m2 on day 1; I: 60 mg/m2/day on days 1, 8 and 15) was administered, whereas ACE (A: 50 mg/m2 on day 1; C: 750 mg/m2 on day 1; E 80 mg/m2/day on days 1-3) was given in the second, fourth and sixth cycles. Each cycle was repeated every 4 weeks. At the end of six cycles, patients who had obtained a complete response were given prophylactic cranial irradiation. Results: In total, 28 patients were enrolled, of whom 27 were assessable for efficacy and safety. Objective responses, including 4 (15%) complete responses, were observed in 25 patients (93%). Median survival time was 12.9 months. The principal toxicity was myelosuppression; grade 4 neutropenia and thrombocytopenia were observed in 89 and 4%, respectively. Febrile neutropenia occurred in 30% of patients. Diarrhea was mild (grade 3-4; 4%). All toxicities were reversible and there were no treatment-related deaths. The mean percentage of the delivered doses, relative to the projected doses, of PI and ACE were 84.6 and 91.1%, respectively. Conclusions: These results indicate the PI-ACE regimen to have promising activity against ED-SCLC with moderate toxicities.

KW - Alternating chemotherapy

KW - Irinotecan

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=34247383102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247383102&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0336-0

DO - 10.1007/s00280-006-0336-0

M3 - Article

C2 - 17393168

AN - SCOPUS:34247383102

VL - 60

SP - 1

EP - 6

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -